IQVIA is a human data science company inspired by the industry they serve and provide solutions that enable life sciences companies to innovate with confidence, maximize opportunities, and ultimately drive human health outcomes forward. Their approach is human data science – a discipline that advances their understanding of human health and allows stakeholders to make better, more insightful decisions and discover breakthroughs. The ROI for research and development within the pharmaceutical industry has decreased from 10.1% in 2010 to just 1.8% over the last ten years. This drastic decrease directly results from fewer drugs being brought to market due to delays in drug development, specifically the regulatory processes with more than 2,000 new or modified FDA regulations since 1998. Working in siloed departments inadvertently creates data silos, preventing valuable data and insights from being shared across departments. These valuable insights could offer more end-to-end visibility to help identify potential issues that could threaten patient safety more quickly, reduce costs, improve efficiencies of regulatory compliance reporting, and open up more opportunities for future innovation. With cross-functional data visibility, pharma companies could take advantage of existing data to optimize the industry's drug development process to bring drugs to market faster. I invited Joe Rymsza, Vice President, Global Pharmacovigilance and Regulatory Technology Solutions at IQVIA, on to the podcast to talk about all this and much more. In his current role, Joe leads a global team of incredibly talented professionals in the US, Europe, Japan, and India that develop, deploy, sell, market, and support IQVIA's leading SaaS, management & technology consulting and hosting and managed services solutions.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related